Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.

Keywords

Riparian zone, Arid, Geography, Environmental science, Agroforestry

References

• Antiretroviral-drug resistance among patients recently infected with HIV.Susan J. Little, Sarah Holte, Jean‐Pierre Routy — 2002
• Triple Nucleoside Combination Zidovudine/Lamivudine/Abacavir versus Zidovudine/Lamivudine/Nelfinavir as First-Line Therapy in HIV-1-Infected Adults: A Randomized TrialSophie Matheron, Diane Descamps, François Boué — 2002
• Mutations in HIV-1 Reverse Transcriptase during Therapy with Abacavir, Lamivudine and Zidovudine in HIV-1-Infected Adults with No Prior Antiretroviral TherapyMounir Ait‐Khaled, Abdelrahim Rakik, Philip Griffin — 2002
• Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent populationDavid R. Bangsberg, Frederick Hecht, Edwin D. Charlebois — 2000
• Impact of protease inhibitors on AIDS‐defining events and hospitalizations in 10 French AIDS reference centresY Mouton, S. Alfandari, M. Valette — 1997
• Discrete sequential boundaries for clinical trialsK. K. Gordon Lan, David L. DeMets — 1983
• Hyperlipidemia and Insulin Resistance Are Induced by Protease Inhibitors Independent of Changes in Body Composition in Patients With HIV InfectionKathleen Mulligan, Carl Grünfeld, Viva Tai — 2000
• Adherence to highly active antiretroviral therapy is better in patients receiving non-nucleoside reverse transcriptase inhibitor-containing regimens than in those receiving protease inhibitor-containing regimens.Maria Paola Trotta, Adriana Ammassari, Alessandro Cozzi‐Lepri — 2003
• Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adultsJohn Bartlett, Ralph DeMasi, Joseph Quinn — 2001
• Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design.Richard Peto, Malcolm C. Pike, P. Armitage — 1976
• Time trends in primary HIV-1 drug resistance among recently infected persons.Robert M. Grant — 2002
• A multiple testing procedure for clinical trials.Peter C. O’Brien, Thomas R. Fleming — 1979
• Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV‐1‐infected patientsRavi Walli, Oliver Herfort, Gerlinde M. Michl — 1998
• Combining dependent tests with incomplete repeated measurementsL. J. Wei, WAYNE E. JOHNSON — 1985
• Group Sequential Methods with Applications to Clinical TrialsKyungMann Kim — 2001
• Treatment‐Related Factors and Highly Active Antiretroviral Therapy AdherenceMaria Paola Trotta, Adriana Ammassari, Sara Melzi — 2002
• The Statistical Analysis of Failure Time DataLaurence L. George — 2003
• Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodeficiency virus type 1: results of the TARGET Study.Keith Henry, Robert Wallace, Paul C. Bellman — 2001
• Response to lamivudine-zidovudine plus abacavir twice daily in antiretroviral-naive, incarcerated patients with HIV infection taking directly observed treatment.Larry R. Kirkland, Margaret A. Fischl, Karen T. Tashima — 2002
• Human Immunodeficiency Virus Type 1 Mutations Selected in Patients Failing Efavirenz Combination TherapyLee T. Bacheler, Elizabeth D. Anton, Phil Kudish — 2000

Cited by

• An Improvement in Virologic Response to Highly Active Antiretroviral Therapy in Clinical Practice From 1996 Through 2002Richard D. Moore, Jeanne Keruly, Kelly A. Gebo — 2005
• Highly active antiretroviral therapy (HAART) in adults with tuberculosis: current status.Awewura Kwara, Timothy Flanigan, E.J. Carter — 2005
• Effectiveness and Safety of Abacavir, Lamivudine, and Zidovudine in Antiretroviral Therapy-Naive HIV-Infected Patients: Results From a Large Multicenter Observational CohortJuan Berenguer, Marı́a Jesús Pérez-Elı́as, José M. Bellón — 2006
• Highly active anti‐retroviral therapy (HAART)‐induced maintenance of adaptive but not innate immune parameters is associated with protection from HIV‐induced mortalityNurdin Riyanto, SU Ir. Pc. Sumardi — 2006
• Metabolic Effects of Protease Inhibitor-Sparing Antiretroviral Regimens Given as Initial Treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095)Javier Plaza Penadés — 2007
• Pediatric HIV infection: the state of antiretroviral therapyAdrienne Andi Sosin, Patricia A. Deleo — 2008
• Clinical audit: virological and immunological response to combination antiretroviral therapy in HIV patients at a Sydney sexual health clinicJ. L. Gregg — 2010
• Comparative effectiveness of continuing a virologically effective first-line boosted protease inhibitor combination or of switching to a three-drug regimen containing either efavirenz, nevirapine or abacavir.Tchadie Bommenel, Odile Launay, Jean Luc Meynard — 2011
• Enhanced identification of synergistic and antagonistic emergent interactions among three or more drugsUrsicino Carrascal Arranz, Beatriz Rodríguez Prado, Yolanda González-Cid — 2016
• Evolution of Resistance Mutations during Low-Level Viral Replication in HIV-1–Infected Patients Treated with Zidovudine/Lamivudine/Abacavir as a First-Line RegimenMartin Stürmer, Brenda Dauer, Manfred Moesch — 2007
• Interpretation of resistance data from randomized trials of first-line antiretroviral treatment.Bonaventura Clotet, Andrew Hill, Yvon van Delft — 2012
• Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in AfricaDART Virology Group and Trial Team — 2006
• Effect of Nucleoside and Nucleotide Reverse Transcriptase Inhibitors of HIV on Endogenous Nucleotide PoolsJennifer E. Vela, Michael D. Miller, Gerald Rhodes — 2008
• Lack of a Metabolic and Antiviral Drug Interaction between Tenofovir, Abacavir and LamivudineAdrian S. Ray, Florence Myrick, Jennifer E. Vela — 2005
• Antiretroviral (ARV) drug resistance in the developing world.Paul Shekelle, Margaret Maglione, Matthew Bidwell Geotz — 2007
• Relationship between Minority NNRTI Resistance Mutations, Adherence, and the Risk of Virologic FailureJonathan Z. Li, Roger Paredes, Heather J. Ribaudo — 2012
• Antiretroviral Therapy: Current DrugsAlice K. Pau, Jomy George — 2014
• [Antiviral treatment regimens].S. Esser — 2006
• Management of individuals requiring ART and TB treatmentKaren Cohen, Graeme Meintjes — 2010
• Analysis of neuropsychiatric adverse events during clinical trials of efavirenz in antiretroviral-naive patients: a systematic review.Brian Gazzard, Andrew Balkin, Andrew Hill — 2010

Related papers

• Great Basin riparian ecosystems: ecology, management and restoration.J. C. Chambers, Jerry R. Miller — 2004
• Riparian Research and Management: Past, Present, Future: Volume 1R. Roy Johnson, Steven W. Carothers, Deborah M. Finch — 2018
• Water Quality Function of Riparian Ecosystems in GeorgiaGeorge Vellidis — 1999
• Riparian areas: perceptions in management.Wayne Elmore, Robert L. Beschta — 1987
• Managing for Enhancement of Riparian and Wetland Areas of the Western United States: An Annotated BibliographyDavid A. Koehler, Allan E. Thomas — 2000
• Riparian research and managementSteven W. Carothers, R. Roy Johnson, Deborah M. Finch — 2020